| Symbol | ACXP |
|---|---|
| Name | ACURX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 259 LIBERTY AVE, STATEN ISLAND, New York, 10305, United States |
| Telephone | +1 917 533-1469 |
| Fax | — |
| — | |
| Website | https://www.acurxpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001736243 |
| Description | Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Additional info from NASDAQ: |
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Read moreNew Form 424B3 - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001104659-26-059298 <b>Size:</b> 222 KB
Read moreNew Form 424B3 - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001104659-26-059296 <b>Size:</b> 156 KB
Read moreAcurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Read moreNew Form S-1 - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001104659-26-054887 <b>Size:</b> 481 KB
Read moreNew Form S-1 - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001104659-26-054884 <b>Size:</b> 433 KB
Read moreAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Read moreDirector Sailer Carl 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046846
Read moreDirector DEAN JACK H 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046844
Read moreDirector Donohue James J. 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046842
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07513285 | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficil… | Phase2 | Clostridium Difficile Infection Recurrence | Not_Yet_Recruiting | 2026-08-19 | 2027-11-24 | ClinicalTrials.gov |
| NCT04247542 | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection | Phase2 | Clostridium Difficile Infection | Completed | 2020-03-06 | 2023-11-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vancomycin | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Ibezapolstat | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Placebo | DRUG | Phase PHASE3 | Tardive Dyskinesia | COMPLETED | NCT02291861 |
| SD-809 | DRUG | Phase PHASE1 | TOURETTE SYNDROME | COMPLETED | NCT02674321 |
| Vancomycin | DRUG | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Ibezapolstat | DRUG | Phase PHASE2 | Clostridium Difficile Infection Recurrence | NOT_YET_RECRUITING | NCT07513285 |